Italian Drug Prices Impact On Jobs, Says Forza Italia MP
Italian drug prices have fallen by about 40% in real terms between 1992 and 1996 - a trend that has brought a "grave worsening" of the results for the Italian pharmaceutical industry, according to Roberto Tortoli, Member of Parliament for Forza Italia, speaking in a parliamentary question session this month.
Mr Tortoli charged that the July 1996 reforms introduced by the government had, moreover, meant a further average reduction in drug prices of 4.2%. He added that the measures envisaged a further reclassification of drugs and medicines in such a way as to entail a strongly-negative impact for drug producers.
The MP said it was not possible to believe that such measures would not also have a damaging effect on jobs and cited the cases of Menarini SpA, which has already announced some 200 job losses (mainly in Tuscany), Cyanamid (100 jobs in Catania) and Crinos (70 jobs at Como).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze